ALK

ALK inhibitors cover anaplastic lymphoma kinase and activin receptor-like kinases, two unrelated groups named ALK. Anaplastic lymphoma kinase was identified in 1994 as a tyrosine kinase fused to nucleophosmin (NPM) in a non-Hodgkin lymphoma. In 2007 a fusion with echinoderm microtubule-associated protein-like 4 (EML4) was found in non-small-cell lung cancer. Crizotinib, TAE684, brigatinib and entrectinib inhibit anaplastic lymphoma kinase, and entrectinib also blocks tropomyosin receptor kinases (Trk). Activin receptor-like kinases (ALKs) are type I receptors for transforming growth factor beta (TGF-β) family ligands. A 83-01 inhibits ALK4, ALK5 and ALK7 and blocks Smad signaling by TGF-β. Vactosertib also targets ALK4 and ALK5, while LDN193189 and DMH-1 inhibit the bone morphogenetic protein receptor ALK2.

Items 126-150 of 150

  • ALK5-IN-30
    Cat. No.
    A34553

    ALK5-IN-30

    ALK5-IN-30 is a potent inhibitor targeting ALK5 and TGFβ-R1, demonstrating IC50 values of less than 10 nM for both proteins. This compound is invaluable for research applications involving modulation of the TGF-β signaling pathway, which plays a critical role in cellular processes such as proliferation, differentiation, and immune response. Its high affinity and selectivity make it an essential tool for studies focused on cancer, fibrosis, and other diseases influenced by ALK signaling.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • J-1048
    Cat. No.
    A34554

    J-1048

    J-1048 is a selective inhibitor of activin receptor-like kinase 5 (ALK5). It effectively inhibits TGF-β/Smad signaling, thereby reducing TAA-induced liver fibrosis in murine models. This compound is valuable for studying the roles of TGF-β signaling in fibrotic diseases and for evaluating therapeutic strategies targeting liver fibrosis.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • DDO-02267
    Cat. No.
    A34555

    DDO-02267

    DDO-02267 is a selective covalent inhibitor of ALKBH5, demonstrating an IC50 value of 0.49 μM. This compound enhances N6-methyladenosine (m6A) levels and modulates the ALKBH5-AXL signaling pathway. DDO-02267 serves as an important tool for elucidating the biological functions of mRNA demethylase in various research contexts.

    Out of stock

    All 3 sizes
  • ALK ligand-1
    Cat. No.
    A34557

    ALK ligand-1

    ALK ligand-1 is a specific ligand for Anaplastic Lymphoma Kinase (ALK). It serves as a critical component in the synthesis of PROTAC ALK degrader-4, facilitating targeted protein degradation. This compound is valuable for research applications aimed at studying ALK-mediated pathways and developing novel therapeutic strategies in oncology.

    Out of stock

    All 3 sizes
  • ALK-IN-9
    Cat. No.
    A34558

    ALK-IN-9

    ALK-IN-9 is a highly potent inhibitor of anaplastic lymphoma kinase (ALK), demonstrating exceptional efficacy in inhibiting cell proliferation with IC50 values of less than 0.2 nM across multiple cell line models, including Ba/F3-EML4-ALK and KG-1 (OP2-FGFR1). This compound is particularly valuable in research applications focused on targeting ALK-driven cancers and exploring the role of ALK in various signaling pathways. Its robust biological activity makes it a critical tool for studying therapeutic resistance and drug development strategies in oncology.

    5 mg
    $795.00
    All 1 sizes
  • PF-03671148
    Cat. No.
    A34560

    PF-03671148

    PF-03671148 is a selective inhibitor of ALK5, a receptor kinase involved in TGFβ signaling. This compound effectively attenuates TGFβ-induced fibrotic gene expression in fibroblasts, making it a promising candidate for research on fibrosis and related conditions. PF-03671148 may hold significant potential for therapeutic applications aimed at preventing dermal scarring and modulating fibrotic responses in various tissues.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • LDN-193688
    Cat. No.
    A34562

    LDN-193688

    LDN-193688 is a selective inhibitor of ALK2, exhibiting IC₅₀ values of 104, 18, 235, 1530, and 1080 nM against ALK1, ALK2, ALK3, ALK4, and ALK5, respectively. This compound effectively inhibits bone morphogenetic protein 4 (BMP4)-induced phosphorylation of SMAD1/5/8, with an IC₅₀ of 2.6 μM. LDN-193688 is utilized in research focused on the BMP signaling pathway and its role in various biological processes, including development and disease.

    1 mg
    $155.00
    5 mg
    $395.00
    All 3 sizes
  • ALK/ROS1-IN-4
    Cat. No.
    A34563

    ALK/ROS1-IN-4

    ALK/ROS1-IN-4 is a selective dual inhibitor targeting the anaplastic lymphoma kinase (ALK) and ROS1 kinases. This compound exhibits potent inhibitory activity against both kinases, making it a valuable tool for studying signaling pathways involved in certain cancers. ALK/ROS1-IN-4 is primarily used in research applications focused on cancer biology and therapeutic development for ALK- and ROS1-positive malignancies.

    Out of stock

    All 3 sizes
  • CEP-28122 mesylate hydrochloride
    Cat. No.
    A34565

    CEP-28122 mesylate hydrochloride

    CEP-28122 mesylate hydrochloride is a selective, orally active inhibitor of the anaplastic lymphoma kinase (ALK) with a reported IC50 of 1.9 nM. Exhibiting significant antitumor activity, it is effective in experimental models of ALK-positive malignancies, including anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma. Its favorable pharmacodynamic and pharmacokinetic properties make it a valuable tool for research into ALK-driven cancers.

    Out of stock

    All 3 sizes
  • Alectinib analog
    Cat. No.
    A34566

    Alectinib analog

    Synonyms: CH5424802 analog; RO5424802 analog; RG7853 analog

    Alectinib analog is a selective inhibitor of Anaplastic Lymphoma Kinase (ALK), specifically designed to overcome resistance via gating mutations. This compound shows low micromolar IC50 values, indicating potent antiproliferative and cytotoxic effects against cancer cells. Its efficacy is linked to enhanced stability and the release of active components. Additionally, Alectinib analog has been demonstrated to inhibit vascular septal dimensions in an in vivo zebrafish model, highlighting its potential for therapeutic applications in cancer research.

    1 mg
    $20.00
    5 mg
    $65.00
    All 7 sizes
  • Zidesamtinib
    Cat. No.
    A35156

    Zidesamtinib

    Synonyms: NVL-520; NUV-520

    Zidesamtinib is a potent, selective inhibitor of ROS1, exhibiting strong activity against various ROS1 fusions and resistance mutations with IC50 values of 0.7 nM for wild-type ROS1 and 7.9 nM for ROS1 G2032R. This orally active compound is designed to penetrate the blood-brain barrier while sparing TRK inhibition. Zidesamtinib is valuable for cancer research, particularly in studies involving ROS1-driven tumors and resistance mechanisms.

    1 mg
    $55.00
    5 mg
    $135.00
    All 7 sizes
  • Taletrectinib free base
    Cat. No.
    A35162

    Taletrectinib free base

    Synonyms: DS-6051b free base; AB-106 free base; IBI-344 free base

    Taletrectinib free base is a selective inhibitor of ROS1 and NTRK signaling pathways, exhibiting potent oral bioactivity. It effectively inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3, with IC50 values of 0.207 nM, 0.622 nM, 2.28 nM, and 0.98 nM, respectively. Additionally, Taletrectinib demonstrates efficacy against ROS1 G2032R and other Crizotinib-resistant ROS1 mutants, making it a valuable tool for cancer research and drug development targeting these pathways.

    1 mg
    $50.00
    5 mg
    $130.00
    All 6 sizes
  • ROS1-IN-1
    Cat. No.
    A35165

    ROS1-IN-1

    ROS1-IN-1 is a potent and selective inhibitor of the ROS1 kinase, exhibiting an IC50 of 0.097 μM. This compound effectively antagonizes ROS1-mediated signaling pathways, making it a valuable tool for research into oncogenic processes associated with ROS1 mutations. It is suitable for studies investigating cancer cell proliferation, survival, and sensitivity to targeted therapies.

    Out of stock

    All 3 sizes
  • ROS1-IN-3
    Cat. No.
    A35168

    ROS1-IN-3

    ROS1-IN-3 is a potent ROS1 inhibitor designed for targeted research in oncology. This compound selectively inhibits the ROS1 receptor tyrosine kinase, making it relevant for the study of non-small cell lung cancer (NSCLC). Its capability to disrupt ROS1-mediated signaling pathways underscores its potential use in preclinical studies evaluating therapeutic strategies for NSCLC.

    Out of stock

    All 3 sizes
  • ROS1-IN-2
    Cat. No.
    A35175

    ROS1-IN-2

    ROS1-IN-2 is a potent ROS1 inhibitor that selectively targets the ROS1 kinase, a critical driver in various cancers. This compound demonstrates significant antitumor activity and is valuable for research into ROS1-driven malignancies. It is particularly useful in studies aimed at understanding the mechanisms of resistance and therapeutic efficacy in cancer treatment strategies.

    Out of stock

    All 3 sizes
  • Depiperazine-DM3189
    Cat. No.
    A37026

    Depiperazine-DM3189

    Synonyms: Depiperazine-LDN-193189

    Depiperazine-DM3189 is an inhibitor of the ALK2 and ALK3 receptors, which are associated with bone morphogenetic protein (BMP) signaling pathways. It exerts significant biological activity by selectively inhibiting the transcriptional activity of these BMP type I receptors, with IC50 values of 5 nM for ALK2 and 30 nM for ALK3. This compound serves as a valuable tool for investigating BMP signaling in various research applications, including the study of diseases such as fibrodysplasia ossificans progressiva.

    1 mg
    $155.00
    5 mg
    $395.00
    All 5 sizes
  • ALKBH5-IN-4
    Cat. No.
    A37805

    ALKBH5-IN-4

    ALKBH5-IN-4 is an inhibitor of the RNA m6A demethylase ALKBH5, exhibiting an IC50 value of 0.84 μM. This compound has demonstrated inhibitory effects on leukemia cells, highlighting its potential role in cancer research. ALKBH5-IN-4 can be utilized to study the biological implications of m6A methylation in various cellular contexts and may serve as a valuable tool in the development of novel therapeutic strategies.

    10 mg
    $25.00
    25 mg
    $55.00
    All 4 sizes
  • CDK12/13 ligand 1
    Cat. No.
    A54481

    CDK12/13 ligand 1

    CDK12/13 ligand 1 is a selective inhibitor of anaplastic lymphoma kinase (ALK), with demonstrated inhibition of tyrosine protein kinases including CDK2/CyclinE1 and focal adhesion kinase (FAK). At a concentration of 10 μM, it exhibits a maximum inhibition of 40.63% on ALK kinase activity. This compound is relevant for anti-cancer research, particularly in studies focusing on targeting ALK-dependent signaling pathways.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • TSR-011-isomer
    Cat. No.
    A76919

    TSR-011-isomer

    TSR-011-isomer is a potent anaplastic lymphoma kinase (ALK) inhibitor with an IC50 of 6 nM. This compound demonstrates significant biological activity by undergoing metabolic hydrolysis and NADPH-dependent metabolism, facilitating its clearance in biological systems. TSR-011-isomer is suitable for research focused on ALK-driven cancers, making it a valuable tool for studies in cancer biology and targeted therapy development.

    25 mg
    $1,655.00
    50 mg
    $2,115.00
    All 3 sizes
  • ALK-IN-35
    Cat. No.
    A84663

    ALK-IN-35

    ALK-IN-35 is an ALK degrader that selectively inhibits ALK kinase activity with an IC50 of 0.74 nM. This compound increases the solvent-accessible surface area of hydrophobic residues around the ALK binding pocket, leading to a partially unfolded conformation that promotes proteasomal degradation of ALK. ALK-IN-35 has demonstrated potent anti-proliferative effects on cancer cells and is a valuable tool for research focused on non-small cell lung cancer.

    Out of stock

    All 3 sizes
  • XMU-MP-5
    Cat. No.
    A84664

    XMU-MP-5

    XMU-MP-5 is a selective inhibitor of anaplastic lymphoma kinase (ALK), demonstrating potent inhibitory activity against ALK-mutated Ba/F3 cells with IC50 values ranging from 4 to 50 nM. This compound induces apoptosis specifically in EML4-ALK Ba/F3 cells and has shown notable antitumor efficacy in murine models. XMU-MP-5 serves as a valuable tool in cancer research, particularly in studies focused on ALK-driven malignancies.

    5 mg
    $245.00
    10 mg
    $405.00
    All 4 sizes
  • Ceritinib mesylate
    Cat. No.
    A84665

    Ceritinib mesylate

    Synonyms: LDK378 mesylate

    Ceritinib mesylate is a selective ALK tyrosine kinase inhibitor that functions through ATP-competitive mechanisms, exhibiting an IC50 of 200 pM. In addition to its activity against ALK, Ceritinib mesylate also inhibits IGF-1R, InsR, and STK22D, with IC50 values of 8 nM, 7 nM, and 23 nM, respectively. This compound demonstrates significant antitumor potency, making it a valuable tool for research in cancer biology and targeted therapies.

    Out of stock

    All 3 sizes
  • A 83-01 sodium
    Cat. No.
    A84792

    A 83-01 sodium

    A 83-01 sodium is a selective inhibitor of the transforming growth factor-beta (TGF-β) type I receptors ALK4, ALK5, and ALK7. With IC50 values of 12 nM, 45 nM, and 7.5 nM, it effectively blocks transcriptional activity induced by these kinases. This compound is valuable for research applications focused on TGF-β signaling pathways and regulation of cellular processes such as proliferation, differentiation, and epithelial-mesenchymal transition.

    1 mg
    $30.00
    5 mg
    $55.00
    All 8 sizes
  • M4K-2009
    Cat. No.
    A84842

    M4K-2009

    M4K-2009 is a potent inhibitor of ALK2, exhibiting an IC50 value of 13 nM, and is capable of penetrating the blood-brain barrier. In addition to its primary activity against ALK2, M4K-2009 demonstrates efficacy against the hERG potassium channel. This compound is valuable for research in the areas of bone morphogenetic protein signaling and related therapeutic applications.

    1 mg
    $155.00
    5 mg
    $395.00
    All 6 sizes
  • TRI-611
    Cat. No.
    B21813

    TRI-611

    TRI-611 is an orally active molecular glue degrader that targets the anaplastic lymphoma kinase (ALK). It forms a ternary complex with the substrate receptor CRBN, leading to polyubiquitination and subsequent degradation of ALK, including resistant fusion proteins. TRI-611 effectively inhibits ALK-mediated downstream signaling and exhibits anti-proliferative effects in ALK-positive cancer cells. Preclinical studies demonstrate its capability to induce regression of ALK-positive non-small cell lung cancer tumors, making it a valuable tool for research into TKI-refractory tumors and central nervous system metastases.

    5 mg
    $590.00
    10 mg
    $905.00
    All 5 sizes

Items 126-150 of 150

Added to your cart

View Cart Checkout

    Loading...